[The latest trends in the treatment peritonitis of the patients on peritoneal dialysis].

Vnitr Lek

Klinika gerontologická a metabolická Lékarské fakulty UK a FN, Hradec Králové.

Published: August 2004

Peritonitis is still one of the major complications ambulatory peritoneal dialysis (CAPD). The initial empiric therapy for peritonitis should be effective against most grampositive organisms as well as gramnegative organisms. Intraperitoneal administration antibiotics has the advantage of a high concentration of the antibiotics at the site of infection. The treatment should provide broad coverage of all organisms, without side-effects or risk for the patient and should not provoke the emergence of resistant germs. The present guidelines of the ad hoc advisory committee are of great value in this regard. The ISPD guidelines for treatment of peritonitis recommended an empirical therapy based on the association of a first-generation cephalosporin with an aminoglycoside or ceftazidime.

Download full-text PDF

Source

Publication Analysis

Top Keywords

treatment peritonitis
8
[the latest
4
latest trends
4
trends treatment
4
peritonitis
4
peritonitis patients
4
patients peritoneal
4
peritoneal dialysis]
4
dialysis] peritonitis
4
peritonitis major
4

Similar Publications

is a very rare pathogen that causes intracranial infection. It is commonly found in immunocompromised patients and is resistant to multiple antibiotics. In this case report, we present a case of human central nervous system infection caused by , which was initially misdiagnosed as demyelinating disease due to the specific imaging findings.

View Article and Find Full Text PDF

Infection with Influenza A virus (IAV) induces severe inflammatory responses and lung injury, contributing significantly to mortality and morbidity rates. Alterations in the microbial composition of the lungs and intestinal tract resulting from infection could influence disease progression and treatment outcomes. Xiyanping (XYP) injection has demonstrated efficacy in clinical treatment across various viral infections.

View Article and Find Full Text PDF

Doxorubicin-induced cardiomyopathy (DOX-IC) is a significant and common complication in patients undergoing chemotherapy, leading to cardiac remodeling and reduced heart function. We hypothesized that the intrapericardial injection of hydrogels derived from the cardiac decellularized extracellular matrix (dECM) loaded with adipose tissue-derived stromal cells (ASC) and their secretome dampens or reverses the progression of DOX-IC. DOX-IC was induced in Wistar male rats through ten weekly intra-peritoneal injections of doxorubicin (cumulative dose: 18 mg/kg).

View Article and Find Full Text PDF

Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death globally, particularly in developing countries in Southeast Asia and sub-Saharan Africa (SSA), where chronic hepatitis B virus (HBV) dominates as a major aetiological factor.

Methods: We conducted a retrospective cohort study to quantify the metastatic profile of HCC in a South African patient population managed at a tertiary centre. Demographic, clinical and treatment data were extracted from an institutional registry.

View Article and Find Full Text PDF

Management of advanced gallbladder adenocarcinoma: A case report and review of treatment strategies.

Int J Surg Case Rep

January 2025

Department of Surgery, School of Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania; University of California, Center for Global Surgery, Sacramento, CA, USA.

Introduction And Importance: Gallbladder cancer (GBC) is a rare but aggressive malignancy, accounting for most biliary tract cancers. It typically presents at an advanced stage, leading to a poor prognosis, with a mean survival of six months and a five-year survival rate of 17.6 %.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!